AgingResearch.NewsJoin free

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate has been studied in 1 paper since 2022: 1 observational study in people. The newest paper, Dec 22, 2022: “Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia”.

Intervention

1 paper studies it3 findingsUpdated

PubChem

See all 1

“Serum potassium level decreased significantly from 5.4 (5.1, 5.9) to 4.4 (4.2, 4.9) mEq/L without any drug-related adverse events”
Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with HyperkalemiaJournal of clinical medicine2022doi:10.3390/jcm12010083

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

About aging: trials about aging, of every trial that tests the drug for any use.

  • 1 lab in 1 country
  • 4 trials, none about aging
  • 4 of 4 trials sponsored by its developers
  • Humans1

What did studies of Sodium zirconium cyclosilicate find?

3

Studies of Sodium zirconium cyclosilicate measured 3 outcomes; the most studied are psoas muscle volume (1 study), nutritional status (1) and serum potassium (1).

Psoas muscle volume

upin humans1

1 study

  1. Sodium zirconium cyclosilicate improves psoas muscle volume in humans (chronic hyperkalemia) (p < 0.05).

    “Psoas muscle volume and average days for one movement also improved significantly during the therapeutic period (p < 0.05 for both).”

    Human trialchronic hyperkalemia3 monthsn = 24

    Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia

    Journal of clinical medicine

More on Psoas muscle volume

Nutritional status

upin humans1

1 study

  1. Sodium zirconium cyclosilicate improves nutritional status in humans (chronic hyperkalemia) (p < 0.05).

    “Nutrition-related scores, including the PNI score, the GNRI score, and the CONUT score, improved significantly following 3 months of SZC therapy (p < 0.05 for all).”

    Human trialchronic hyperkalemia3 monthsn = 24

    Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia

    Journal of clinical medicine

Serum potassium

downin humans1

1 study

  1. Sodium zirconium cyclosilicate decreases serum potassium in humans (chronic hyperkalemia) (from 5.4 (5.1, 5.9) to 4.4 (4.2, 4.9) mEq/L).

    “Serum potassium level decreased significantly from 5.4 (5.1, 5.9) to 4.4 (4.2, 4.9) mEq/L without any drug-related adverse events”

    Human trialchronic hyperkalemia3 monthsn = 24

    Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia

    Journal of clinical medicine

More on Serum potassium

Who is developing Sodium zirconium cyclosilicate?

1 company: AstraZeneca.

Companies
  • AstraZenecaPhase 3chronic renal insufficiency, hyperkalemia

Trial sponsors

Latest

Related